Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
ChemoCentryx Stock Forecast NASDAQ:CCXI
Price Target and Analyst Ratings
Most Recent Rating
On Nov 10, 2021 "Raymond James" gave "$107.00 - $110.00" rating for CCXI. The price target was set to $38.86+2.2%.
Last 30 Days
Historical Ratings
| Date | Rating | Action | Authority | Current Price | Target Price |
|---|---|---|---|---|---|
| 2021-11-10 | $107.00 - $110.00 | Target Raised by | Raymond James | $37.99 | $38.86+2.2% |
| 2021-11-09 | Reiterated by | SVB Leerink | $38.02 | $38.51→2.2% | |
| 2021-10-11 | $14.00 - $38.00 | Upgraded by | JPMorgan Chase & Co. | $40.50 | $38.64+0.6% |
| 2021-10-11 | $64.00 | Upgraded by | SVB Leerink | $40.50 | $38.41+96.0% |
| 2021-10-08 | Upgraded by | Piper Sandler | $38.41 | $36.11+84.2% | |
| 2021-10-08 | $62.00 - $107.00 | Upgraded by | Raymond James | $38.41 | $36.11+84.2% |
| 2021-10-08 | $31.00 - $85.00 | Target Raised by | Stifel Nicolaus | $38.41 | $37.86+93.2% |
| 2021-10-08 | $28.00 - $101.00 | Target Raised by | HC Wainwright | $38.41 | $38.41+96.0% |
| 2021-08-11 | $79.00 - $64.00 | Target Lowered by | Canaccord Genuity | $14.41 | $14.31→2.0% |
| 2021-07-07 | Buy | Reiterated by | Canaccord Genuity | $14.47 | $79.00 |
| 2021-07-06 | Hold - Buy | Upgraded by | Stifel Nicolaus | $14.05 | |
| 2021-05-13 | Outperform - Market Perform | Reiterated by | SVB Leerink | $9.97 | $84.00 → $17.00 |
| 2021-05-13 | Buy - Hold | Reiterated by | Stifel Nicolaus | $9.97 | $93.00 → $26.00 |
| 2021-05-13 | Neutral - Underweight | Reiterated by | JPMorgan Chase & Co. | $9.97 | $57.00 → $17.00 |
| 2021-05-13 | Strong-Buy - Outperform | Reiterated by | Raymond James | $9.97 | $120.00 → $51.00 |
| 2021-05-13 | Buy | Target Lowered by | HC Wainwright | $9.97 | $101.00 → $28.00 |
| 2021-05-12 | Overweight - Neutral | Reiterated by | Piper Sandler | $10.05 | $80.00 → $25.00 |
| 2021-05-07 | Buy | Target Lowered by | HC Wainwright | $10.46 | $101.00 → $28.00 |
| 2021-05-07 | Buy - Hold | Downgraded by | Stifel Nicolaus | $10.46 | |
| 2021-05-07 | Neutral - Underweight | Downgraded by | JPMorgan Chase & Co. | $10.46 | $57.00 → $17.00 |
| 2021-05-07 | Outperform - Market Perform | Downgraded by | SVB Leerink | $10.46 | |
| 2021-05-07 | Strong-Buy - Outperform | Downgraded by | Raymond James | $10.46 | $120.00 → $51.00 |
| 2021-05-06 | Overweight - Neutral | Downgraded by | Piper Sandler | $27.49 | |
| 2021-05-05 | Buy | Reiterated by | Canaccord Genuity | $27.49 | |
| 2021-03-08 | Buy | Initiated by | Stifel Nicolaus | $55.29 | $93.00 |
| 2021-03-08 | Strong-Buy | Target Raised by | Raymond James | $55.29 | $119.00 → $120.00 |
| 2021-03-02 | Buy | Target Raised by | HC Wainwright | $66.80 | $83.00 → $101.00 |
| 2021-03-02 | Strong-Buy | Target Raised by | Raymond James | $66.80 | $119.00 → $120.00 |
| 2021-03-01 | Buy | Initiated by | Stifel Nicolaus | $68.40 | |
| 2021-01-08 | Strong-Buy | Target Raised by | Raymond James | $62.78 | $100.00 → $119.00 |
| 2020-10-29 | Overweight - Neutral | Downgraded by | JPMorgan Chase & Co. | $49.52 | $63.00 → $60.00 |
| 2020-10-29 | Overweight | Target Raised by | Piper Sandler | $49.52 | $67.00 → $71.00 |
| 2020-10-29 | Outperform | Target Raised by | SVB Leerink | $49.52 | $75.00 → $84.00 |
| 2020-10-29 | Overweight | Target Lowered by | Wells Fargo & Company | $49.52 | $79.00 → $70.00 |
| 2020-09-17 | Target Raised by | HC Wainwright | $52.57 | $73.00 → $85.00 | |
| 2020-08-12 | Outperform | Target Raised by | SVB Leerink | $52.99 | $65.00 → $75.00 |
| 2020-08-12 | Outperform | Target Raised by | SVB Leerink | $52.99 | $65.00 → $75.00 |
| 2020-08-11 | Strong-Buy | Target Raised by | Raymond James | $53.66 | $95.00 → $100.00 |
| 2020-07-29 | Overweight | Target Lowered by | JPMorgan Chase & Co. | $52.65 | $64.00 → $61.00 |
| 2020-06-16 | Buy | Initiated by | BTIG Research | $62.16 | $70.00 |
| 2020-06-03 | Buy | Reiterated by | Canaccord Genuity | $60.58 | |
| 2020-05-27 | Overweight | Initiated by | Wells Fargo & Co | $63.14 | $79.00 |
| 2020-05-19 | Buy | Target Lowered by | Canaccord Genuity | $56.02 | $68.00 → $58.00 |
| 2020-05-18 | Reduce - Overweight | Target Raised by | Piper Sandler | $58.49 | $54.00 → $70.00 |
| 2020-05-14 | Overweight | Target Raised by | JPMorgan Chase & Co. | $52.22 | $61.00 → $64.00 |
| 2020-05-12 | Buy | Target Raised by | Canaccord Genuity | $56.52 | $64.00 → $68.00 |
| 2020-05-12 | Buy | Target Raised by | HC Wainwright | $56.52 | $60.00 → $69.00 |
| 2020-05-12 | Strong-Buy | Target Raised by | Raymond James | $56.52 | $38.00 → $102.00 |
| 2020-05-12 | Outperform | Target Raised by | SVB Leerink | $56.52 | $54.00 → $65.00 |
CCXI Stock Trend
The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $35.46 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift.
Given the current short-term trend, the stock is expected to rise 89.24% during the next 3 months and, with a 90% probability hold a price between $67.11 and $109.40 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2021-12-09 | $35.90 | $47.07 | $58.24 |
| 2021-12-10 | $36.33 | $47.50 | $58.67 |
| 2021-12-13 | $36.76 | $47.93 | $59.11 |
| 2021-12-14 | $37.19 | $48.37 | $59.54 |
| 2021-12-15 | $37.63 | $48.80 | $59.97 |
| 2021-12-16 | $38.06 | $49.23 | $60.40 |
| 2021-12-17 | $38.49 | $49.66 | $60.84 |
| 2021-12-20 | $38.92 | $50.10 | $61.27 |
| 2021-12-21 | $39.36 | $50.53 | $61.70 |
| 2021-12-22 | $39.79 | $50.96 | $62.14 |
| 2021-12-23 | $40.22 | $51.40 | $62.57 |
| 2021-12-27 | $40.66 | $51.83 | $63.00 |
| 2021-12-28 | $41.09 | $52.26 | $63.43 |
| 2021-12-29 | $41.52 | $52.69 | $63.87 |
| 2021-12-30 | $41.95 | $53.13 | $64.30 |
| 2021-12-31 | $42.39 | $53.56 | $64.73 |
| 2022-01-03 | $42.82 | $53.99 | $65.16 |
| 2022-01-04 | $43.25 | $54.42 | $65.60 |
| 2022-01-05 | $43.68 | $54.86 | $66.03 |
| 2022-01-06 | $44.12 | $55.29 | $66.46 |
| 2022-01-07 | $44.55 | $55.72 | $66.90 |
| 2022-01-10 | $44.98 | $56.16 | $67.33 |
| 2022-01-11 | $45.41 | $56.59 | $67.76 |
| 2022-01-12 | $45.85 | $57.02 | $68.19 |
| 2022-01-13 | $46.28 | $57.45 | $68.63 |
| 2022-01-14 | $46.71 | $57.89 | $69.06 |
| 2022-01-17 | $47.15 | $58.32 | $69.49 |
| 2022-01-18 | $47.58 | $58.75 | $69.92 |
| 2022-01-19 | $48.01 | $59.18 | $70.36 |
| 2022-01-20 | $48.44 | $59.62 | $70.79 |
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase I... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
